The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...

AbbVie (NYSE: ABBV) stock rose 4.2% after the drugmaker forecast 2025 profit above estimates, as strong sales of its newer ...

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...

Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...